Not all sufferers with CLL need therapy. Even with all current innovations, the iwCLL nevertheless endorses watchful observation for patients with asymptomatic condition.86 This recommendation is based on a minimum of two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR